"Eurotox 2005; 42nd Congress of European Societes of Toxicology" . "[F45A9972F7EE]" . "K\u00EDzek, Ren\u00E9" . . . "7"^^ . . "CPSA; metallothionein; platinum-based drugs"@en . "The influence of platinum-based drugs on the amount of metallothionein" . "2"^^ . . "P(GP525/04/P132)" . . "43210" . . . "Kukacka, J." . "Neoplastic diseases represent one of the most prevalent human disorders. Many of those are generally treated by platinum-complexes. Effectiveness of such treatment depends on the therapeutic concentration of the drug, commonly influenced by binding to proteins (e.g. metallothionein). Metallothionein (MT) is a well-known molecular protein maintaining metal ion homeostasis. The aim of this work was to study the interaction of MT with Pt compounds. The proper interaction was observed in our experiments in vitro by means of electrochemical techniques using the oxidation-reduction and/or catalytic signals (metallothionein-SH groups reduction, Brdicka reaction, and H-peak). Our suggested technique was used for blood serum analysis from the patients treated with standard platinum compounds. The MT amount was increased more than 10 times in these patients\u00B4serum in comparison with non-treated patients. The results thus show that the MT amount has a significant negative influence on the therapy of neoplastic d"@cs . "The influence of platinum-based drugs on the amount of metallothionein"@en . "Zehn\u00E1lek, Josef" . . "4"^^ . "Bla\u0161t\u00EDk, Ond\u0159ej" . "Vliv platinov\u00FDch l\u00E9\u010Div na obsah metalothioneinu"@cs . "Pr\u016F\u0161a, Richard" . "Adam, Vojt\u011Bch" . "524787" . "0378-4274" . . "RIV/62156489:43210/05:00007603!RIV06-GA0-43210___" . "The influence of platinum-based drugs on the amount of metallothionein"@en . "RIV/62156489:43210/05:00007603" . . . . . "S66;S67" . "Petrlov\u00E1, Jitka" . . "Elsevier" . . "Neoplastic diseases represent one of the most prevalent human disorders. Many of those are generally treated by platinum-complexes. Effectiveness of such treatment depends on the therapeutic concentration of the drug, commonly influenced by binding to proteins (e.g. metallothionein). Metallothionein (MT) is a well-known molecular protein maintaining metal ion homeostasis. The aim of this work was to study the interaction of MT with Pt compounds. The proper interaction was observed in our experiments in vitro by means of electrochemical techniques using the oxidation-reduction and/or catalytic signals (metallothionein-SH groups reduction, Brdicka reaction, and H-peak). Our suggested technique was used for blood serum analysis from the patients treated with standard platinum compounds. The MT amount was increased more than 10 times in these patients\u00B4serum in comparison with non-treated patients. The results thus show that the MT amount has a significant negative influence on the therapy of neoplastic d"@en . "The influence of platinum-based drugs on the amount of metallothionein" . . . "Vliv platinov\u00FDch l\u00E9\u010Div na obsah metalothioneinu"@cs . "Neoplastic diseases represent one of the most prevalent human disorders. Many of those are generally treated by platinum-complexes. Effectiveness of such treatment depends on the therapeutic concentration of the drug, commonly influenced by binding to proteins (e.g. metallothionein). Metallothionein (MT) is a well-known molecular protein maintaining metal ion homeostasis. The aim of this work was to study the interaction of MT with Pt compounds. The proper interaction was observed in our experiments in vitro by means of electrochemical techniques using the oxidation-reduction and/or catalytic signals (metallothionein-SH groups reduction, Brdicka reaction, and H-peak). Our suggested technique was used for blood serum analysis from the patients treated with standard platinum compounds. The MT amount was increased more than 10 times in these patients\u00B4serum in comparison with non-treated patients. The results thus show that the MT amount has a significant negative influence on the therapy of neoplastic d" . .